Clinical Trial Update: A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy results for mepolizumab (Nucala) in subjects with severe asthma were completed and results posted in 2024. The sponsor was GlaxoSmit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Nucala (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2024-09-19